Skip to content
OpenCapital
Get started

Clarivate CLVT Life Sciences & Healthcare — Adjusted EBITDA

Similar metrics at other companies

International Flavors & Fragrances logo
IFFHealth & Biosciences — Adjusted Operating EBITDA
$153M+10.9%
IDEX logo
IEXHealth & Science Technologies — Segment Adjusted EBITDA
$106M+21.3%
International Flavors & Fragrances logo
IFFHealth & Biosciences — Segment Adjusted Operating EBITDA
$153M+10.9%
AdaptHealth logo
AHCODiabetes Health — Adjusted EBITDA
$4.14M-35.2%
Clorox logo
CLXHealth and Wellness — Segment Adjusted EBIT
$158M-6.5%
Ashland logo
ASHLife Sciences — Earnings Before Interest Tax Depreciation And Amortization
$49M-9.3%

Other financials

Income statement

See full
Revenue$585.5M-1.4%
Gross profit$393.4M+1.7%
Operating income$30.2M+245%
Net income-$40.2M+61.3%
EPS (diluted)-$0.06+60.0%

Balance sheet

See full
Cash & equivalents$242.2M-31.6%
Total debt$4.4B-5.7%
Total equity$4.8B-4.7%
Total assets$10.9B-4.9%

Cash flow

See full
Operating cash flow$134.7M-21.3%
CapEx$55.8M-8.4%
Free cash flow$78.9M-28.5%

Valuation

See full
Market cap$1.28B-40.1%
Enterprise value$5.45B-17.7%
P/S0.5×-0.3×

Profitability

See full
Gross margin66.5%+0.5pp
Operating margin5%+2.9pp
Net margin-5.7%-2.5pp
FCF margin13.6%-0.4pp

Returns & leverage

See full
Return on equity-2.9%-1.2pp
Debt / equity0.9×0.0×
Current ratio0.8×0.0×

Where this comes from

Reported directly by Clarivate in its filing.

Tagged under the XBRL concept clvt:AdjustedEBITDA.

The official record: Clarivate’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Clarivate's life sciences & healthcare — adjusted ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Clarivate's life sciences & healthcare — adjusted EBITDA?
Clarivate (CLVT) reported life sciences & healthcare — adjusted EBITDA of $29.2M in Q1 2026.
How has Clarivate's life sciences & healthcare — adjusted EBITDA changed year-over-year?
Clarivate's life sciences & healthcare — adjusted EBITDA decreased by 4.6% year-over-year, from $30.6M to $29.2M.
What is the long-term trend for Clarivate's life sciences & healthcare — adjusted EBITDA?
Over 3 years (2022 to 2025), Clarivate's life sciences & healthcare — adjusted EBITDA has grown at a -13.4% compound annual growth rate (CAGR), from $184.2M to $119.7M.
What does life sciences & healthcare — adjusted EBITDA mean?
This metric measures the operational profitability of the Life Sciences & Healthcare segment by excluding non-cash items like depreciation, amortization, and one-time restructuring charges. It is the primary benchmark for evaluating the segment's core cash-generating capability and operational performance.